Suggested remit: To appraise the clinical and cost effectiveness of dupilumab within its marketing authorisation for treating moderate to severe chronic obstructive pulmonary disease (COPD).
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6235
Project Team
- Project lead
- Jennifer Upton
Email enquiries
If you have any queries please email [email protected]
Stakeholders
- Companies sponsors
- Sanofi
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Asthma + Lung UK
- Professional groups
- Association of Respiratory Nurse Specialists
- British Thoracic Society
- Primary Care Respiratory Society UK
- Royal College of Physicians
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Astrazeneca UK Ltd
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary (BNF)
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- National Institute for Health & Care Research
- Technology Assessment Programme (NETSCC)
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 August 2025 | Committee meeting: 2 |
| 24 April 2025 - 16 May 2025 | Draft guidance: 1 |
| 01 April 2025 | Committee meeting |
| 28 August 2024 | Invitation to participate |
| 16 May 2024 - 14 June 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6235 |
| 15 May 2024 | In progress. Scoping commenced. |
| 23 February 2024 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during late August 2024 when we will write to you about how you can get involved. |
| 18 January 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual